MK-7602 Phase 1 Clinical Trial Results: WEHI's New Antimalarial Drug Reaches a Major Milestone
Phase 1 Clinical Trials of MK-7602: A Promising New Chapter in the Fight Against Malaria
From Laboratory Discovery to Human Trials
Every new antimalarial medicine begins with a simple question: Can scientists stay ahead of one of humanity's oldest and most adaptable killers?
For decades, malaria parasites have repeatedly evolved resistance to medicines that once transformed global malaria control. Each time a highly effective treatment has been introduced, the parasite has eventually found new ways to survive, creating an urgent need for drugs with entirely different mechanisms of action.
In March 2026, researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI) reached an important milestone in that ongoing battle. Early clinical trial results showed that the experimental antimalarial drug MK-7602 was well tolerated in healthy volunteers and achieved blood concentrations predicted to effectively kill malaria parasites.
Although Phase 1 clinical trials are designed primarily to evaluate safety rather than effectiveness, these encouraging findings represent the first time this first-in-class dual plasmepsin inhibitor has successfully completed first-in-human testing. More importantly, they mark the transition of nearly a decade of laboratory research into the earliest stage of clinical medicine.
What Is MK-7602?
MK-7602 is a first-in-class dual plasmepsin inhibitor jointly developed by WEHI and MSD (Merck & Co.). Unlike current antimalarial medicines that typically target a single parasite pathway, MK-7602 simultaneously inhibits two essential malaria enzymes, plasmepsin IX (PMIX) and plasmepsin X (PMX). These enzymes are critical for parasite invasion, growth inside red blood cells, and transmission to mosquitoes.
By blocking both enzymes at the same time, researchers hope to create a treatment that is more difficult for malaria parasites to evade through genetic mutation, potentially slowing the emergence of drug resistance.
The Story Behind the Discovery
MK-7602 did not appear overnight. It is the result of nearly a decade of collaboration between Professor Alan Cowman and colleagues at WEHI and scientists at MSD. The project began with high-throughput compound screening at Australia's National Drug Discovery Centre (NDDC), located at WEHI.
After identifying promising chemical hits, medicinal chemists optimized the compounds while biologists investigated how they interfered with parasite biology. This close partnership between academic researchers and pharmaceutical scientists eventually produced MK-7602—a drug candidate with activity against both Plasmodium falciparum and Plasmodium vivax, the two most important malaria parasites affecting humans.
What Happened in the Phase 1 Trials?
The Phase 1 clinical program consisted of two studies evaluating single ascending doses and multiple ascending doses in healthy adult volunteers.
- MK-7602 was generally well tolerated.
- No major safety concerns were identified.
- The most commonly reported adverse event was mild headache.
- Drug exposure reached levels predicted to provide antimalarial activity.
These studies also provided valuable pharmacokinetic data that will guide dose selection in future clinical trials.
Why Is This Important?
Current frontline antimalarial drugs are increasingly threatened by parasite resistance, particularly in Southeast Asia and parts of Africa. New medicines with completely different mechanisms of action are urgently needed.
Because MK-7602 targets two essential parasite enzymes simultaneously, laboratory studies suggest it has a much higher barrier to resistance than many existing therapies. If confirmed in later-stage trials, this strategy could help extend the useful lifespan of future malaria treatments.
Recognition
The significance of this research has also been recognised nationally. In 2026, the WEHI-led research team behind this work was named a finalist for the Australian Museum Eureka Prize, Australia's most prestigious science awards. The recognition highlights decades of collaborative research that progressed from fundamental discoveries in malaria biology to the development of a promising new generation of antimalarial medicines.
What Comes Next?
Following successful Phase 1 safety studies, MK-7602 is progressing into studies designed to evaluate its antimalarial activity against Plasmodium falciparum infection under controlled clinical conditions. These trials will determine whether the promising laboratory findings translate into effective parasite clearance in humans.
Although many experimental drugs never reach approval, Phase 1 represents one of the most significant milestones in drug development. For WEHI, it also demonstrates how decades of curiosity-driven research can ultimately produce entirely new medicines with the potential to save millions of lives.
Conclusion
MK-7602 represents far more than another experimental antimalarial drug. It reflects nearly a decade of collaboration between WEHI and MSD, transforming fundamental discoveries in malaria parasite biology into a promising new therapeutic strategy.
The successful completion of Phase 1 clinical trials does not yet prove that MK-7602 can cure malaria, but it does show that this first-in-class dual plasmepsin inhibitor has safely reached one of the most important milestones in drug development. The next challenge is to determine whether these encouraging laboratory findings translate into effective parasite clearance in patients.
Whether MK-7602 ultimately becomes an approved medicine remains to be seen. Even so, its journey already demonstrates how decades of curiosity-driven research can evolve into innovative treatments with the potential to improve global health.